Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc AGRX

Alternate Symbol(s):  AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a... see more

Recent & Breaking News (OTCPK:AGRX)

Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage

Accesswire July 11, 2023

H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch

Accesswire July 5, 2023

This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023

Accesswire July 3, 2023

Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?

Accesswire June 30, 2023

The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care

Accesswire June 28, 2023

Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members

GlobeNewswire June 26, 2023

Agile Therapeutics Commends the Biden Administration's Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services

GlobeNewswire June 23, 2023

Agile Therapeutics Announces the Availability of Twirla® through FPA Women's Health

GlobeNewswire June 15, 2023

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

GlobeNewswire June 13, 2023

Agile Therapeutics Announces Closing of $7.5 Million Public Offering

GlobeNewswire May 25, 2023

Agile Therapeutics Announces Pricing of $7.5 Million Public Offering

GlobeNewswire May 22, 2023

Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update

GlobeNewswire May 11, 2023

Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023

GlobeNewswire May 8, 2023

Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

GlobeNewswire April 28, 2023

Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire April 26, 2023

Agile Therapeutics Announces 1-For-50 Reverse Stock Split

GlobeNewswire April 10, 2023

Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 22, 2023

Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023

GlobeNewswire March 21, 2023

Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

GlobeNewswire February 27, 2023

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

PR Newswire February 15, 2023